The miracle weight loss drug, sold as injection 'pens' for £170, is appearing on drug menus alongside ADHD medication Ritalin ...

Semaglutide use in patients with type 2 diabetes moderately increases the risk of nonarteritic anterior ischemic optic neuropathy.

Semaglutide is a glucagon-like peptide-1 (GLP-1) that helps regulate blood sugar levels. Because of outsized demand for ...

British patients with obesity undergoing hip and knee replacements had less of a need for subsequent revision when, after surgery, they lost weight by using medications such as GLP-1 receptor agonists ...

The shortage of semaglutide injections (Ozempic, Wegovy) is over, the FDA announced on Friday. The agency, along with maker ...

For patients with type 2 diabetes (T2D) and chronic obstructive pulmonary disorder (COPD), sodium-glucose cotransporter-2 inhibitors (SGLT-2is) and glucagon-like peptide-1 receptor agonists (GLP-1 RAs ...

Senn develops and manufactures, peptides and peptides-based applications for its global customers, providing contract research, development, and manufacturing services.

WEIGHT loss jabs could raise the risk of a “potentially blinding condition” known as an “eye stroke”, researchers have warned ...

Treatment for OUD is currently dominated by opioid agonist therapies that are highly regulated due to their liability for abuse.

Two Omaha women lost more than 300 lbs. combined with injections of a GLP-1 drug, which are used increasingly for weight loss ...

A randomized, placebo-controlled trial validates a side effect frequently observed by doctors and patients. A new study from ...

“I am pleased to be joining Terns as we advance our lead oncology and obesity programs towards important clinical readouts later this year,” said Mr. Azelby. “I look forward to working with Terns’ ...